Why Rapid Immunoassays And Gc-Ms Work Better Together In Diagnostic Screening

The Laboratory That Cannot Afford to Treat Every Sample the Same

At 8:00 a.m., a laboratory may receive hundreds of specimens.

Most will be negative. A small number will contain the target analyte. Fewer still will require a result that can withstand clinical, regulatory, or legal scrutiny.

The operational mistake is to process every sample as though it carries the same level of uncertainty.

Running every specimen through GC-MS or LC-MS/MS offers excellent analytical certainty, but it also ties up expensive instruments, skilled operators, and preparation capacity. Screening every sample with a rapid immunoassay is efficient, but a presumptive positive may not provide enough molecular specificity for a final decision.

The stronger system gives each method the job it is best equipped to perform:

Rapid immunoassays clear the easy negatives at scale.
Chromatographic methods investigate the difficult positives with precision.

This is not a compromise between speed and accuracy. It is a division of labor.

A Two-Stage System for Two Different Questions

A screening workflow usually asks two different questions.

Could the target be present?
Which compound is present, and at what concentration?

Rapid immunoassays are designed for the first question. GC-MS and LC-MS/MS are designed for the second.

That distinction matters because no analytical method is equally optimized for throughput, accessibility, specificity, and cost.

Workflow question	Best-fit method	Typical role
Could this sample contain the target?	Rapid immunoassay	High-throughput screening
Is the target definitively present?	GC-MS or LC-MS/MS	Confirmation and quantification
Can testing occur close to the patient or collection site?	Lateral flow immunoassay	Portable or point-of-care screening
Does the result need detailed molecular evidence?	Chromatography-mass spectrometry	Definitive identification

The result is a funnel.

A large number of samples enter through the broad end. Most are rapidly classified as negative. Only the smaller group that requires additional scrutiny moves to the more demanding analytical stage.

What Immunoassays Do Well

An immunoassay converts molecular recognition into a practical signal.

Its central component is an antibody selected to recognize a drug, biomarker, pathogen-related antigen, or target class. In ELISA formats, the signal can be measured across a plate or automated analyzer. In lateral flow formats, the result can often be interpreted visually or with a compact reader.

This makes immunoassays valuable where laboratories face volume, time pressure, or limited instrumentation.

Speed

Many rapid formats produce results in approximately 10 to 30 minutes.

That changes the workflow around the test. Samples do not necessarily need to wait for a central laboratory queue before an initial decision can be made.

Throughput

A laboratory can screen hundreds of specimens more economically than it could run every specimen through mass spectrometry.

The value is not only the speed of an individual test. It is the number of routine samples removed from the high-complexity pathway.

Accessibility

Lateral flow tests require minimal equipment and can support decentralized testing. Automated immunoassays can bring standardized screening into emergency departments, clinics, occupational health programs, and other settings where a mass spectrometer is impractical.

Operational simplicity

Sample preparation is often simpler than the extraction and separation steps required for chromatography.

This reduces the dependence on highly specialized operators during the first stage of testing. It also makes the method easier to integrate into a repeatable routine.

Why a Positive Immunoassay Is Not the Final Answer

The same biological recognition that makes immunoassays fast can introduce ambiguity.

An antibody is not always limited to one perfectly isolated molecule. Structurally related metabolites, degradation products, or chemical analogs may bind to it as well. Their combined signal can make the apparent concentration higher than the concentration of the specific compound measured by chromatography.

This is called cross-reactivity.

It does not mean the immunoassay has failed. It means the result must be interpreted according to the method's intended role.

A positive immunoassay result is often best understood as:

This sample has entered the zone where a more specific method is justified.

That is a useful result. It protects the laboratory from spending the resources required to confirm every sample, while ensuring that an ambiguous sample does not become an overconfident final report.

How Chromatography Resolves the Ambiguity

GC-MS and LC-MS/MS answer a narrower question with much greater molecular specificity.

Chromatography first separates compounds within a sample. Mass spectrometry then identifies them according to their characteristic mass patterns and measures their concentration against calibrated reference standards.

This provides several capabilities that a rapid immunoassay cannot fully reproduce:

Specific molecular identification
Accurate quantitative measurement
Separation of closely related compounds
Stronger evidence for regulated, clinical, and forensic reporting
A defensible reference result for assay validation

The instrument is slower and more demanding because the analytical task is more demanding.

A mass spectrometer is not merely a more expensive screening device. It is a resolution tool for the cases in which a broad biological signal is no longer sufficient.

The Economics of the Screening Funnel

Suppose a laboratory receives 1,000 specimens and 90 percent are negative.

Running all 1,000 samples through GC-MS would create a large analytical burden. Running a rapid immunoassay first may reduce the number of samples requiring confirmation to a much smaller subset.

The exact economics depend on prevalence, cutoff selection, reagent cost, sample preparation, instrument utilization, and labor. The principle remains stable: reserve the most expensive analytical capacity for the specimens that need it most.

Consideration	Rapid immunoassay	GC-MS or LC-MS/MS
Primary function	Frontline screening	Definitive confirmation
Typical turnaround	Approximately 10–30 minutes	Hours to days, depending on workflow
Instrument requirement	Minimal or automated analyzer	High-complexity instrumentation
Sample preparation	Often simple	Frequently more extensive
Operator requirements	Lower during routine screening	Highly trained personnel
Result type	Presumptive qualitative or semi-quantitative result	Specific identification and quantification
Cost per routine sample	Lower	Higher
Best use	Large sample populations	Presumptive positives and complex cases

The system becomes financially rational because it does not ask a high-complexity instrument to solve a low-complexity problem.

Correlation Is Designed, Not Assumed

The quality of the overall workflow depends on the quality of the screening reagent.

A poorly optimized immunoassay can generate excessive false positives, overwhelming the confirmation laboratory. A test with inadequate sensitivity can allow relevant samples to pass through as apparent negatives.

The development target is therefore not simply a fast test. It is a fast test that behaves predictably against a trusted reference method.

Several development decisions influence that behavior:

Selection of highly specific primary antibodies
Characterization of cross-reactivity against likely interferents
Optimization of antibody concentration and pairing
Control of matrix effects
Calibration against an appropriate chromatographic reference
Validation across the intended concentration range
Definition of cutoffs according to the clinical or screening objective

In well-optimized systems, the correlation coefficient between immunoassay results and a chromatographic reference may exceed R² = 0.95.

That figure should be interpreted carefully. A high correlation supports the immunoassay as a credible screening tool, but it does not erase the difference between correlation and molecular confirmation.

A screening method can track a reference method closely while still requiring confirmation for positive results.

The Confirmation Protocol Is Part of the Assay

A kit cannot carry the entire burden of reliability by itself.

The laboratory must also define what happens after a presumptive positive appears. Without a clear handoff, the screening stage may be efficient while the overall system remains vulnerable.

A robust protocol should specify:

The cutoff that triggers confirmation
Whether borderline results are repeated
Which samples require GC-MS or LC-MS/MS
How samples are labeled and transferred
How storage and chain of custody are maintained
Which calibration and quality-control materials are required
Who may authorize a final report
How discrepant screening and confirmation results are investigated

This is where many workflows become fragile.

The confirmation instrument may be available, but the sample may not be logged correctly. The laboratory may have a cutoff, but no rule for an equivocal result. A positive sample may be transferred between departments without a documented chain of custody.

Analytical rigor is a process property. It comes from the interaction of reagent design, instrument performance, sample handling, and decision rules.

Managing the Confirmation Bottleneck

The screening stage can reduce workload, but it can also concentrate it.

If the positive rate is higher than expected, or if the cutoff is too permissive, the confirmation queue may become the new point of failure. Samples accumulate. Turnaround times expand. Operators begin to prioritize informally, and the consistency of the workflow deteriorates.

Laboratories can manage this risk by modeling the handoff before deployment.

Estimate the expected positive volume

The anticipated prevalence determines how many samples are likely to reach confirmation. A low-prevalence population may require only a small confirmation capacity. A high-risk population may require much more.

Set cutoffs for the mission

A cutoff designed for maximum sensitivity may produce more presumptive positives. A cutoff designed for rapid triage may prioritize speed and negative predictive value.

Neither is universally correct. The cutoff must reflect the consequences of missed positives, unnecessary confirmations, and delayed decisions.

Separate clear negatives from ambiguous results

Clear negatives can often be released quickly when the assay has been properly validated. Unexpected or borderline positives should follow a defined repeat or confirmation path.

Protect instrument capacity

Confirmation capacity should be treated as a planned resource, not an afterthought. Instrument time, operator availability, consumables, calibration schedules, and sample preparation space all affect the real throughput of the system.

Choosing the Right Balance for the Application

The best workflow depends on what failure would cost the organization most.

Field screening and maximum portability

Use lateral flow immunoassays as the primary entry point when samples must be tested outside a central laboratory.

The majority of decisions can be made quickly and locally. Presumptive positives can be retained under controlled conditions and transported for GC-MS or LC-MS/MS confirmation.

Forensic and legally defensible reporting

Use a sensitive immunoassay for efficient initial screening, followed by mandatory chromatographic confirmation of every presumptive positive.

The first method controls workload. The second method provides the molecular evidence needed for a final report.

Emergency and clinical triage

An automated immunoassay analyzer can support rapid decisions where treatment or patient management cannot wait for a full chromatographic workflow.

The laboratory should define when an unexpected, borderline, or clinically inconsistent result must be escalated. Speed is valuable, but it must not turn a preliminary signal into an unjustified conclusion.

Monitoring a well-characterized population

Where prevalence is known to be low and the assay has strong negative predictive performance, immunoassays can handle most of the workload.

Validation against the reference method is especially important. A demonstrated correlation such as R² > 0.95, combined with appropriate sensitivity and specificity studies, can reduce unnecessary confirmations while preserving a defensible analytical strategy.

What Diagnostic Developers Need from Their Supply Chain

A screening-to-confirmation workflow begins long before the first patient or field sample is tested.

Diagnostic manufacturers need raw materials that behave consistently across development and scale-up. Laboratories need reagents that fit existing instruments and validation plans. Research institutes need technical support while translating an assay concept into a reproducible method.

The material decision can influence:

Antibody specificity and cross-reactivity
Signal strength and assay sensitivity
Lot-to-lot consistency
Matrix compatibility
Calibration performance
Stability and storage requirements
Transfer from prototype to production
The comparability of immunoassay results with GC-MS or LC-MS/MS

This is why raw-material sourcing should be connected to technical decision-making.

CamelBio supports diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting. That support covers the path from concept to clinic, where reagent selection, assay optimization, reference-method comparison, and workflow design must remain aligned.

The objective is not to make the immunoassay replace chromatography.

The objective is to make both methods work as one coherent system.

A Practical Design Checklist

Before implementing or scaling a paired workflow, confirm that the team can answer the following questions:

What is the immunoassay intended to screen for?
Which compounds or metabolites may create cross-reactivity?
What concentration range matters for the intended use?
Which cutoff triggers confirmation?
What happens to borderline or invalid results?
What percentage of samples is expected to require confirmation?
Is the GC-MS or LC-MS/MS capacity sufficient for that volume?
Which reference materials and controls will be used?
How will screening results be compared with chromatographic results?
Which findings can be reported immediately, and which require confirmation?
How will sample identity and chain of custody be preserved?
Are the raw materials and technical processes stable enough for scale-up?

These questions convert a pair of analytical methods into an operating model.

The Core Principle

Immunoassays and chromatographic methods represent different kinds of intelligence.

The immunoassay recognizes a meaningful pattern quickly. Chromatography separates that pattern into molecular facts.

One protects time and budget. The other protects certainty.

When the antibodies are carefully selected, cross-reactivity is characterized, cutoffs are appropriate, and every presumptive positive follows a defined confirmation protocol, the combined workflow becomes more than the sum of its parts.

It gives laboratories the speed to process reality at scale and the precision to defend the cases that matter most.

For help selecting IVD raw materials, optimizing immunoassay performance, and connecting development decisions from concept to clinic, Contact Our Experts.